An update on the treatment of hemangiomas in children with interferon alfa-2a

Archives of Otolaryngology - Head and Neck Surgery

Volumn 125, Issue 1, 1999, Pages 21-27

  Greinwald Jr , John H ^a   Burke, Diane K ^a   Bonthius, Daniel J ^a   Bauman, Nancy M ^a   Smith, Richard J H ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON;

ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; HEMANGIOMA; HUMAN; IMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 0033020354     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.125.1.21     Document Type: Article

References (34)

1. Jacobs AH, Walton RG. The incidence of birthmarks in the neonate. Pediatrics. 1976;58:218-221.
2. Amir J, Metzker A, Krikler R, Reiser SH. Strawberry hemangioma in preterm infants. Pediatr Dermatol. 1986;3:331-332.
3. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life threatening hemangiomas of infancy. N Engl J Med. 1992;326:1456-1463.
4. Wever TR, Connors RH, Tracy TF, Bailey PV. Complex hemangiomas of infants and children. Arch Surg. 1990;125:1017-1021.
5. Enjolras O, Riche MC, Merland JJ, Escande JP. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics. 1990;85:491-498.
6. Ohlms LA, Jones OT, McGill TJ, Healy JB. Interferon alfa-2a therapy for airway hemangiomas. Ann Otol Rhinol Laryngol 1994;103:1-8.
7. White CW, Sondheimer HM, Croach EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomatosis with recombinant Interferon alta-2a. N Engl J Med. 1989; 320:1197-1200.
8. Orchard PJ, Smith CM, Woods WG, Day DL, Dahner LP, Shapiro R. Treatment of hemangioendotheliomas with alia Interferon. Lancet. 1989;2:1565-1567.
9. MacArthur CJ, Senders CW, Katz J. The use of interferon alfa-2a for life-threatening hemangiomas. Arch Otolaryngol Head Neck Surg. 1995;121:690-693.
10. Blei F, Isakoff M, Deb G. The response of parotid hemangiomas to the use of systemic Interferon alfa-2a or cortical steroids. Arch Otolaryngol Head Neck Surg. 1997;123:841-844.
11. Chang E, Boyd A, Nelson CC, et al. Successful treatment of infant hemangiomas with Interferon α-2b. J Pediatr Hematol Oncol. 1997;19:237-244.
12. Bauman NM, Burke DK, Smith RJH. Treatment of massive or life-threatening hemangiomas with recombinant α-2a Interferon. Otolaryngol Head Neck Surg. 1997; 117:99-110.
13. Myer JS, Hoffer FA, Barnes PD. et al Biologie classification of soft tissue vascular anomalies: MR correlation. AJR Am J Roentgenol. 1991;157:559-564.
14. Baker LL, Dillon WP, Hieshima GB, Dowd CF, Frieden IJ. Hemangiomas and vascular malformations of the head and neck: MR characterization. AJNR Am J Neuroradiol. 1993;14:307-314.
15. Mullikan JB, Fellows KE, Strand RD. Childhood hemangiomas and vascular formations: angiographic differentiation. AJR Am J Roentgenol. 1983;141:483-488.
16. Fishman S J, Mulliken JB. Hemangiomas and vascular malformations of infancy and childhood. Pediatr Clin North Am. 1993;40:1177-1200.
17. Sloan GM, Reinisch JF, Nichter LS, Saber WL, Lew K, Morwood DT. Intralesional corticosteroid therapy for infantile hemangiomas. Plast Reconstr Surg. 1989;83:459-466.
18. Cowan FJ, Warner JT, Dunstan FD, Evans WD, Gregory JW, Jenkins HR. Inflammatory bowel disease and predisposition to osteopenia. Arch Dis Child. 1997; 76:325-329.
19. Bartoshesky LE, Bull M, Feingold M. Corticosteroid treatment of cutaneous hemangiomas: how effective? a report of 24 children. Clin Pediatr. 1978;17:2625-2638.
20. Ideo G, Bellati G, Pedraglio E, Leandro G. One year of therapy of nonA, nonB/C chronic hepatitis with recombinant α-2a interferon (r-IFN) or lymphoblastoid α Interferon (I-IFN). J Hepatol. 1990;11(suppl 2):S31.
21. Antonelli G, Currenti M, Turriziani O, Dianzani F. Frequency of neutralizing antibodies to interferon alpha in patients treated with different interferon alfa preparations. J Infect Dis. 1991;163:882-885.
22. Antonelli G, Giannelli G, Current M. et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alfa 2 therapy. Clin Exp Immunol. 1996;104:384-387.
23. Cirelli R, Tyring SK. Major therapeutic uses of interferons Clin Immunother. 1995; 3:27-87.
24. Jones GJ, Itri LM. Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients. Cancer 1986;57:1709-1715.
25. Kemeny N, Younes A, Seiter K. et al. Interferon alfa-2a and 5-fluorouracil for advanced colorectal carcinoma: assessment of activity and toxicity. Cancer. 1990; 66:2470-2475.
26. Pazdur R, Ajani JJ, Abbruzzese JL, et al. Phase II evaluation of fluorouracil and recombinant α-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer. 1992;70:2073-2076.
27. Fosså SD, Gunderson R, Moe B. Recombinant interferon-alfa combined with prednisone in metastatic renal cell carcinoma: reduced toxicity without reduction of the response rate: a phase II study. Cancer. 1990;65:2451-2454.
28. Bauherz G, Soeur M, Lustman F. Oculomotor nerve paralysis induced by alpha II-interferon, Acta Neurol Belg. 1990;90:111-114.
29. Krown SE, Gold JWM, Niedzwiecki D, et al. Interferon-α with zidovudine: safety, tolerance, and clinical and virologie effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990;112:812-821.
30. Ernstoff MS, Nair S, Bahnson RR, et al. A phase 1A trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 1990;8:1637-1649.
31. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998;132:527-530.
32. Moreno MR, Jimenez J, Porres JC, Bartolomé J, Moreno A, Carreño V. A controlled trial of recombinant interferon-alfa in Caucasian children with chronic hepatitis B Digestion. 1990;45:26-33.
33. Utili R, Sagnelli E, Gaeta GB, et al. Treatment of chronic hepatitis B in children with prednisone followed by alfa-interferon: a controlled randomized study. J Hepatol. 1994;20:163-167.
34. Bruguera M, Amat L, Garcia D, et al. Treatment of chronic hepatits B in children with recombinant alfa interferon: different response according to age at infection. J Clin Gastroenterol. 1993;17:296-299.